Lenvatinib monotherapy promoted production of CD8+ T-cells, Tregs, tumour infiltrating macrophages and polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs), with increased numbers of the latter postulated in treatment resistance. Here, CD8A is linked to neoplasm.